AU781113B2 - Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease - Google Patents

Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease Download PDF

Info

Publication number
AU781113B2
AU781113B2 AU22878/01A AU2287801A AU781113B2 AU 781113 B2 AU781113 B2 AU 781113B2 AU 22878/01 A AU22878/01 A AU 22878/01A AU 2287801 A AU2287801 A AU 2287801A AU 781113 B2 AU781113 B2 AU 781113B2
Authority
AU
Australia
Prior art keywords
biologically active
compound
subject
vitamin
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU22878/01A
Other languages
English (en)
Other versions
AU2287801A (en
Inventor
Colleen E. Hayes
Faye E. Nashold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of AU2287801A publication Critical patent/AU2287801A/en
Assigned to WISCONSIN ALUMNI RESEARCH FOUNDATION reassignment WISCONSIN ALUMNI RESEARCH FOUNDATION Assignment by Applicant under S 113 Assignors: NORTHERN LIGHTS PHARMACEUTICALS, LLC
Application granted granted Critical
Publication of AU781113B2 publication Critical patent/AU781113B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
AU22878/01A 1999-12-21 2000-12-21 Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease Ceased AU781113B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/469,985 US6358939B1 (en) 1999-12-21 1999-12-21 Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
US09/469985 1999-12-21
PCT/US2000/034913 WO2001046132A1 (en) 1999-12-21 2000-12-21 Use of biologically active vitamin d compounds for the prevention and treatment of inflammatory bowel disease

Publications (2)

Publication Number Publication Date
AU2287801A AU2287801A (en) 2001-07-03
AU781113B2 true AU781113B2 (en) 2005-05-05

Family

ID=23865828

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22878/01A Ceased AU781113B2 (en) 1999-12-21 2000-12-21 Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease

Country Status (9)

Country Link
US (2) US6358939B1 (enExample)
EP (1) EP1240136A4 (enExample)
JP (1) JP2004502638A (enExample)
KR (1) KR100660508B1 (enExample)
AU (1) AU781113B2 (enExample)
CA (1) CA2395200A1 (enExample)
MX (1) MXPA02006257A (enExample)
NO (1) NO326517B1 (enExample)
WO (1) WO2001046132A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087350A (en) 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
WO2001042205A2 (en) * 1999-12-02 2001-06-14 The Penn State Research Foundation Treatment of inflammatory bowel disease with vitamin d compounds
US6989377B2 (en) * 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
EP2071332A1 (en) * 2000-11-14 2009-06-17 Techlab, Inc. Method for monitoring persons with IBD using total endogeneous lactoferrin as a marker
US7582670B2 (en) * 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
EP1587906A2 (en) * 2003-01-10 2005-10-26 Eli Lilly And Company Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators
EP1603530A1 (en) * 2003-03-04 2005-12-14 Teva Pharmaceutical Industries Limited Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
GB0307865D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
US20050148557A1 (en) * 2003-07-29 2005-07-07 Jin Tian Use of Vitamin Ds to treat kidney disease
US20050209203A1 (en) * 2003-07-30 2005-09-22 Jin Tian Use of vitamin Ds or vitamin D analogs to treat cardiovascular disease
US20060171983A1 (en) * 2003-07-30 2006-08-03 Jin Tian Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease
US20050192255A1 (en) * 2003-07-30 2005-09-01 Jin Tian Use of Vitamin Ds or Vitamin D analogs to treat cardiovascular disease
US7704980B2 (en) * 2003-10-08 2010-04-27 Wisconsin Alumni Research Foundation Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
GB0513984D0 (en) * 2005-07-07 2005-08-17 Teva Pharma Dosage form
US10716798B2 (en) 2007-02-21 2020-07-21 The Regents Of The University Of Michigan Compositions and methods for tranquilizing heart muscle
EP2139462B1 (en) * 2007-03-30 2014-01-22 Amgen Inc. Calcimimetic compounds for use in the treatment of bowel disorders
JP2010524973A (ja) * 2007-04-18 2010-07-22 ジョンズ ホプキンス ユニバーシティ カルシトリオールの低カルシウム血性、高抗増殖性類似体
US8318708B2 (en) * 2007-11-06 2012-11-27 Salk Institute For Biological Studies Use of vitamin D receptor agonists, ligands, and precursors to treat pancreatic fibrosis
EP2217250A4 (en) 2007-11-09 2011-01-05 California Inst Of Techn IMMUNOMODULATING COMPOUNDS AND RELEVANT COMPOSITIONS AND METHODS
AU2010208323B2 (en) 2009-01-27 2016-03-10 Berg Llc Vitamin D3 and analogs thereof for alleviating side effects associated with chemotherapy
EP2464357B1 (en) 2009-08-14 2019-05-22 Berg LLC Vitamin d3 and analogs thereof for treating alopecia
ES2524127T3 (es) 2009-11-20 2014-12-04 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidinodiamina y sus profármacos y sus usos
HUE040658T2 (hu) 2010-04-07 2019-03-28 California Inst Of Techn Vivõanyag vegyület mukózus membránhoz juttatásához és kapcsolódó készítmények, eljárások és rendszerek
CA2792278C (en) 2010-04-13 2019-05-14 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and prodrugs thereof and their uses
US20130064859A1 (en) * 2011-01-28 2013-03-14 Sarkis K. Mazmanian Combinatorial vitamin d and probiotic therapy for inflammatory bowel disease
EP2731617A4 (en) 2011-07-12 2015-07-01 Brigham & Womens Hospital LIPID-BASED PSA COMPOSITIONS, METHOD FOR THEIR INSULATION AND USE METHOD THEREFOR
HUE025567T2 (en) * 2011-08-19 2016-02-29 Maria Clementine Martin Klosterfrau Vertriebsges Mbh Agents containing vasoconstrictors for combination therapy
CA2909941A1 (en) 2013-04-24 2014-10-30 Salk Institute For Biological Studies Vitamin d receptor/smad genomic circuit gates fibrotic response
WO2014182966A1 (en) 2013-05-10 2014-11-13 California Institute Of Technology Probiotic prevention and treatment of colon cancer
SG10201709894RA (en) 2013-05-29 2018-01-30 Berg Llc Preventing or mitigating chemotherapy induced alopecia using vitamin d
BR112015030518A2 (pt) 2013-06-05 2017-08-29 Salk Inst For Biological Studi Composição farmacêutica, uso de um ou mais agonistas do receptor da vitamina d (vdr), e, método para a redução da atividade biológica do ligante 12 do motivo c-x-c (cxcl12)
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
KR102343093B1 (ko) 2015-02-23 2021-12-24 삼성전자주식회사 식기 세척기 및 그 제어방법
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
JP6918365B2 (ja) 2015-08-19 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 脂質化ｐｓａ組成物および方法
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
WO2019023149A1 (en) 2017-07-24 2019-01-31 Salk Institute For Biological Studies USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES
EP4593867A2 (en) 2022-09-30 2025-08-06 Extend Biosciences, Inc. Long-acting parathyroid hormone

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030326A1 (en) * 1995-03-30 1996-10-03 The Trustees Of The University Of Pennsylvania Differentiating agents for the treatment of inflammatory intestinal diseases
EP0927721A1 (de) * 1997-12-17 1999-07-07 Schering Aktiengesellschaft Neue Vitamin D-Derivate mit Phosphoratomen in den Seitenketten, Zwischenprodukte bei ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln
AU4510001A (en) * 1999-12-02 2001-06-18 Penn State Research Foundation, The Treatment of inflammatory bowel disease with vitamin d compounds

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4312806A (en) 1981-03-02 1982-01-26 G. D. Searle & Co. Method and compounds for treating inflammatory bowel disease
US4638043A (en) 1984-11-13 1987-01-20 Thermedics, Inc. Drug release system
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5824313A (en) 1989-09-25 1998-10-20 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US5518725A (en) 1989-09-25 1996-05-21 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US5643602A (en) 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
US5216002A (en) 1989-12-21 1993-06-01 Eli Lilly And Company Method of treating inflammatory bowel disease
JP2811353B2 (ja) 1990-07-06 1998-10-15 ゼリア新薬工業株式会社 炎症性腸疾患予防・治療剤
ZA916555B (en) 1990-08-27 1993-04-28 Lilly Co Eli Method of treating inflammatory bowel disease
US5391555A (en) 1991-11-12 1995-02-21 Miles Inc. Methods for treating inflammatory bowel disease with leukotriene synthesis inhibitors
DE4141746A1 (de) 1991-12-13 1993-06-17 Schering Ag 20-methyl-substituierte vitamin d-derivate
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
DK64592D0 (da) 1992-05-14 1992-05-14 Carlbiotech Ltd As Peptider til terapeutisk behandling
DE4221961A1 (de) * 1992-06-30 1994-01-05 Schering Ag 22-En-25-oxa-Derivate in der Vitamin D-Reihe, Verfahren zu ihrer Herstellung, diese Derivate enthaltenen pharmazeutische Präparate sowie deren Verwendung als Arzneimittel
US5294630A (en) 1992-07-07 1994-03-15 Eli Lilly And Company Treatment of inflammatory bowel disease
US5368854A (en) 1992-08-20 1994-11-29 Schering Corporation Use of IL-10 to treat inflammatory bowel disease
IL107185A (en) * 1992-10-06 1998-02-22 Schering Ag Vitamin d, 25-carboxylic acid derivatives and pharmaceutical compositions containing the same
GB9223061D0 (en) 1992-11-04 1992-12-16 Leo Pharm Prod Ltd Chemical compounds
DE59409873D1 (de) 1993-04-20 2001-10-25 Hexal Ag Wirkstoffpflaster
GB9309422D0 (en) 1993-05-07 1993-06-23 Res Inst Medicine Chem Chemical compounds
GB9314400D0 (en) 1993-07-12 1993-08-25 Leo Pharm Prod Ltd Produktionsaktieselskab) chemical compounds
GB9315253D0 (en) 1993-07-23 1993-09-08 Res Inst Medicine Chem Chemical compounds
US5420109A (en) 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents
GB9325415D0 (en) 1993-12-13 1994-02-16 Res Inst Medicine Chem Chemical compounds
DE4405545A1 (de) * 1994-02-22 1995-08-31 Dietl Hans Fettlösliche Vitamine enthaltende Zubereitung zur oralen Applikation
GB9405715D0 (en) 1994-03-23 1994-05-11 Res Inst Medicine Chem Chemical compounds
GB2292079B (en) 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
ES2130522T3 (es) 1994-12-14 1999-07-01 Duphar Int Res Compuestos de vitamina d y metodo para preparar estos compuestos.
WO1996022973A1 (fr) 1995-01-23 1996-08-01 Chugai Seiyaku Kabushiki Kaisha Derives de vitamine d3 de 2-substitution
US5877168A (en) 1995-02-10 1999-03-02 Chugai Seiyaku Kabushiki Kaisha Vitamin D derivative with substituent at the 2β-position
US5569680A (en) 1995-02-13 1996-10-29 Trustees Of The Univ. Of Penna Method of treating inflammatory bowel disease with tributyrin
GB9509764D0 (en) 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
US5851548A (en) 1995-06-07 1998-12-22 Gen-Probe Incorporated Liposomes containing cationic lipids and vitamin D
DK0836506T4 (da) 1995-06-07 2012-01-30 Ortho Mcneil Pharm Inc Transdermalt plaster til indgivelse af 17-deacetyl norgestimat alene eller i kombination med et østrogen
US5711964A (en) 1995-06-07 1998-01-27 United States Of America Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
US5952317A (en) 1995-09-21 1999-09-14 Wisconsin Alumni Research Foundation Calcitriol derivatives and their uses
DE69606680T2 (de) 1995-10-30 2000-08-17 F. Hoffmann-La Roche Ag, Basel 1-Alpha, 26-dihydroxy-D-homo-vitamin D3
US5889028A (en) 1996-02-09 1999-03-30 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5716946A (en) 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment
AU710931B2 (en) 1996-02-28 1999-09-30 Sumitomo Pharmaceuticals Company, Limited Crystalline vitamin D derivative
GB9607034D0 (en) 1996-04-03 1996-06-05 Leo Pharm Prod Ltd Chemical compounds
US5834016A (en) 1996-04-04 1998-11-10 Cilag Ag Liposome-based topical vitamin D formulation
US5891865A (en) 1996-10-04 1999-04-06 Wisconsin Alumni Research Foundation Treatment of arthritic disease induced by infectious agents
DE69834109T2 (de) * 1997-05-16 2007-04-19 Woman & Infants Hospital 3-epi-vitamin d2 verbindungen und ihre anwendungen
NL1006072C2 (nl) 1997-05-16 1998-11-17 Jacobs Johannes J Vergister voor het onder aërobe omstandigheden vergisten van dierlijke mest, inrichting en werkwijze voor het onder aërobe omstandigheden vergisten van dierlijke mest onder toepassing van een dergelijke vergister.
WO1998051678A1 (en) * 1997-05-16 1998-11-19 Women & Infants Hospital CYCLIC ETHER VITAMIN D3 COMPOUNDS, 1α (OH) 3-EPI-VITAMIN D3 COMPOUNDS AND USES THEREOF
US5936105A (en) 1997-06-13 1999-08-10 Tetrionics, Inc. 14-EPI-19-nor-vitamin D compounds and methods
US6214373B1 (en) * 1999-10-07 2001-04-10 Snowden-Sutton Associates, Inc. Nutritional composition for treating inflammatory bowel diseases
US20030188756A1 (en) * 2002-08-19 2003-10-09 Cantorna Margherita T Treatment of inflammatory bowel disease with vitamin d compounds
MXPA03001969A (es) * 2000-09-08 2003-06-24 Wisconsin Alumni Res Found 1-alfa-hidroxi-2-metilen-19-nor-homopregnacalciferol y sus aplicaciones terapeuticas.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030326A1 (en) * 1995-03-30 1996-10-03 The Trustees Of The University Of Pennsylvania Differentiating agents for the treatment of inflammatory intestinal diseases
EP0927721A1 (de) * 1997-12-17 1999-07-07 Schering Aktiengesellschaft Neue Vitamin D-Derivate mit Phosphoratomen in den Seitenketten, Zwischenprodukte bei ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln
AU4510001A (en) * 1999-12-02 2001-06-18 Penn State Research Foundation, The Treatment of inflammatory bowel disease with vitamin d compounds

Also Published As

Publication number Publication date
US6358939B1 (en) 2002-03-19
KR100660508B1 (ko) 2006-12-22
JP2004502638A (ja) 2004-01-29
NO20022974L (no) 2002-08-20
EP1240136A1 (en) 2002-09-18
US20020128241A1 (en) 2002-09-12
NO20022974D0 (no) 2002-06-20
KR20020084075A (ko) 2002-11-04
AU2287801A (en) 2001-07-03
WO2001046132A1 (en) 2001-06-28
EP1240136A4 (en) 2004-05-26
NO326517B1 (no) 2008-12-22
MXPA02006257A (es) 2004-12-06
CA2395200A1 (en) 2001-06-28
US6858595B2 (en) 2005-02-22

Similar Documents

Publication Publication Date Title
US6358939B1 (en) Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
US6989377B2 (en) Treating vitamin D responsive diseases
Yamamoto et al. Immunological effects of vitamin D and their relations to autoimmunity
JP6463714B2 (ja) 二次性副甲状腺機能亢進症の治療及び予防方法
Laverny et al. Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease
Cantorna et al. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence
Limketkai et al. Role of vitamin D in inflammatory bowel disease
Branisteanu et al. Prevention of murine experimental allergic encephalomyelitis: cooperative effects of cyclosporine and 1 α, 25-(OH) 2D3
Coyne et al. Differential effects of acute administration of 19-Nor-1, 25-dihydroxy-vitamin D2 and 1, 25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients
Horrobin et al. The nutritional regulation of T lymphocyte function
McAllister Jr et al. Malignant hypertension: effect of therapy on renin and aldosterone
RU2322984C2 (ru) Комбинации для лечения иммуновоспалительных расстройств
WO2009047644A2 (en) Method of treating vitamin d insufficiency and deficiency
CA2370230C (en) Treatment of systemic lupus erythematosis
EP1392323B1 (en) Use of a vitamin d3 analogue for the treatment of autoimmune diabetes
Hwang et al. Ontogenic regulation of components of ileal bile acid absorption
KR20000048821A (ko) 관절염의 치료를 위해 비타민 ｄ 유사체를 사용하는 방법
Favus et al. Idiopathic hypercalciuria and nephrolithiasis
WO2023110855A1 (en) Compositions for treating autoimmune arthritis
JP2003516386A (ja) ビタミンｄ化合物での炎症性腸疾患の治療
Klein Progress in understanding calcium and vitamin D endocrinology following burn injury in children
Eastcott et al. Autoimmune Thyroiditis with Raised 131I Uptake
RS66629B1 (sr) Perinatalna primena fruktooligosaharida kratkog lanca u cilju sprečavanja metaboličkih poremećaja povezanih sa neuravnoteženom ishranom u odraslom dobu
Moeniralam et al. 107. Opiate analgesia modulates the inflammatory, endocrine and metabolic responses to endotoxin in dogs
WO2021117824A1 (ja) インクレチン産生促進剤及び糖取り込み促進剤

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: WISCONSIN ALUMNI RESEARCH FOUNDATION

Free format text: THE FORMER OWNER WAS: NORTHERN LIGHTS PHARMACEUTICALS, LLC